Investing in a healthy future
Generating superior returns by investing in and building sustainable and leading healthcare businesses
With a Nordic base
Impilo is an investment company focused on investments in Nordic companies operating in the pharmaceutical, medical techonology, healthcare and care services and other health-related industries
Redefining success
Our starting point is that our portfolio companies must contribute to a positive and sustainable development of the societies and markets in which they operate, in order to remain successful in the long-term
Investments
We invest in companies to which we can offer knowledge, capital and new perspectives and thus create momentum to implement change and achieve ambitious goals. Our portfolio consists of market-leading healthcare companies with significant growth potential in the Nordics and beyond.
Our team
Who we are
At Impilo, we are a diverse team with the necessary sector-specific knowledge, experience, and passion to be a responsible and active partner to the companies in which we invest in. We believe that our employees are our most important assets and seek to create a workplace where the team is more important than the individual.
News
Impilo Closes €320m Single Asset Continuation Fund Transaction to Support the Continued Growth of Immedica Pharma
On 20th September 2024, Impilo, a Nordic healthcare investment firm and KKR, a leading global investment firm, announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm, focused on the commercialization of medicines for rare diseases and specialty care products.
Impilo and KKR Completes Joint Acquisition of Immedica Pharma
Stockholm and London, 19 September 2024 – KKR, a leading global investment firm, and Impilo, a Nordic healthcare investment firm, have today announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm and focused on the commercialization of medicines for rare diseases and specialty care products.
Scantox Group acquires Gentronix
Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization (“CRO”), well recognized for its high-quality genetic toxicology services and strong scientific engagement.
Impilo acquires Qufora in partnership with existing shareholders
Impilo is now the majority shareholder in the Danish medtech company Qufora, which produces clinical aids for patients with chronic bowel conditions. This partnership will enable Qufora to accelerate its international expansion.